miophthalmology products

BOC Instruments has released AutoFusion – Optovue’s latest optical coherence tomography (OCT) device. This dual modality integrated OCT and fundus camera is simple to use, with a fully automated, streamlined operation and 3D auto tracking. It automatically aligns, focuses, tracks and captures with a single tap. The AutoFusion OCT is compact with an integrated PC and a tiltable LCD touch screen. It delivers high-resolution OCT images and 12-megapixel true colour retinal photos.

Features include comprehensive retinal, glaucoma, anterior and pachymetry analysis reports, as well as optic nerve and macular analysis from a single 3D wide scan. 3D imaging includes progressive Early Treatment Diabetic Retinopathy Study (ETDRS) thickness maps, and ganglion cell complex analysis. Optic nerve head (ONH) scanning provides progressive retinal nerve fibre layer and ONH parameter evaluation. Scan options include 5-line, cross, wide line, radial, corneal/anterior scans including pachymetry maps and angles. Trend analysis reports highlight structural changes and detailed quantitative assessment.

BOC Instruments supplies a range of OCT models to suit requirements and budget. Current Optovue OCT models are the AutoFusion, i-Scan80, i-Vue80, Solix Essential, and Solix FullRange with optional corneal topography functions.

Contact: BOC Instruments (AUS) 1800 804 or visit bocinstruments.com.au

The Topcon Triton2 is a next-generation multimodal swept-source optical coherence tomography (OCT) device that delivers high-density, deep-penetration imaging with impressive clinical versatility. With 1,050 nm wavelength and high-speed scanning, it offers clear visualisation of retinal and choroidal structures, even through media opacities, reducing motion artefacts and minimising rescans. Triton2 combines true-colour fundus imaging with innovative slit-scan technology for small pupils, plus optional wide-field OCT/OCT-angiography up to 21 mm for comprehensive retinal assessment. Powered by Imagenet7 with Smart Denoise, it enhances image quality, quantitative mapping, and follow-up comparisons. Features such as the Hood Report support glaucoma diagnosis, while optional anterior segment imaging broadens diagnostic capability and streamlines workflow.

Contact: Device Technologies eyes@device.com.au

Early functional change in macular disease often precedes visible structural damage. Retimax enables clinicians to detect these subtle alterations through objective electrophysiological testing, including multifocal electroretinogram, pattern electroretinogram, and visual evoked potentials testing. Published clinical studies have shown that biofeedback training with Retimax can significantly improve best-corrected visual acuity, contrast sensitivity and fixation stability in patients with macular degeneration, while also enhancing reading performance and quality of life.1

For practices focused on proactive care, the real advantage lies in earlier detection and intervention – identifying macular dysfunction before optical coherence tomography changes become pronounced. This allows timely referral, closer monitoring, and improved patient outcomes. By combining diagnostic precision with evidence-based visual rehabilitation, Retimax positions practices at the forefront of functional retinal assessment and modern low-vision management.

Visit: eyetek.com.au

Spectralis is a multimodal retinal imaging platform designed to support the diagnosis and monitoring of macular disease. Confocal scanning laser ophthalmoscopy (cSLO), combined with high-resolution spectral-domain optical coherence tomography (OCT), enables simultaneous fundus and cross-sectional imaging with precise point-to-point correlation, helping clinicians visualise retinal microstructure in detail.

The Shift technology allows OCT scan speeds to be adapted to clinical needs: high-sensitivity 20 kHz scanning improves image quality in difficult-to-image eyes with media opacities, while 125 kHz scanning is optimised for OCT angiography to evaluate macular microvasculature. BluePeak fundus autofluorescence combined with OCT is widely used to assess and monitor geographic atrophy progression. TruTrack active eye tracking, ART image averaging, and AutoRescan support high-quality images and precise follow up for monitoring macular disease over time.

Contact: Heidelberg Engineering (AUS) 1300 454 357 or sales-au@heidelbergengineering.com

iCare’s Maia microperimeter provides precise, clinically relevant assessment of macular function by measuring retinal sensitivity and correlating results directly with fundus imaging. Advanced eye-tracking technology ensures that stimuli are delivered accurately, even in patients with unstable fixation, enabling reliable and reproducible functional testing.

Maia generates detailed retinal sensitivity maps and fixation analysis, helping clinicians detect subtle functional deficits, monitor disease progression, and evaluate treatment response over time. By revealing changes that may not be apparent with structural imaging or visual acuity alone, Maia enhances understanding of macular disease and supports informed clinical decision making. Its focus on functional assessment provides an essential complement to anatomical imaging, making it a valuable tool in patient management.

Contact: iCare World (AUS) 0435 788 702 or inquiry@icare-world.com

Ellex’s Integre Pro Scan combines multi-colour photocoagulation in an ergonomically advanced all-in-one laser/slit lamp design.

Whether delivering focal or grid treatment to the macula – where precision is paramount to preserve central vision – or performing pan-retinal photocoagulation (PRP) in the periphery, Integre Pro Scan provides a comprehensive selection of patterns and wavelengths to confidently address the full spectrum of retinal pathologies.

Contact: Ellex (AUS) 08 7074 8200 or visit lumibirdmedical.com/ophthalmology

MDeyes Once Daily soft gel capsules deliver a complete low zinc macular health formulation, as presented in a landmark clinical study.1 Appropriate for the Australian context, this low zinc formula also features the precise, high-quality ingredients used in a previous study,2 including FloraGlo lutein and Optisharp zeaxanthin.

MDeyes’ quality formula is enhanced by calendarised packaging, ensuring daily patient compliance, with blister-packaging to help maintain the freshness of each capsule. MDeyes Once Daily soft gel capsules are Australian made in a world-class facility. Affordability is a priority, and generous wholesale margins are available for stockists.

Not sold in pharmacy.

Contact: MDeyes (AUS) 07 3056 0960 or (NZ) 0800 443 652 or info@mdeyes.com.au

Nutravision is an award winning, zinc-free eye supplement for patients who want nutritional support for long-term healthy vision, eye comfort, and macular health. Built on the peer reviewed NP 10 System,1 it addresses key pathways that help support macular health, including blood circulation, antioxidant support, and cell energy production.

Each capsule delivers evidence-informed ingredients for macular support, including lutein and zeaxanthin (Lutemax 2020), saffron (affron), ginkgo biloba, vegan vitamin D3, and methylated B vitamins.

Nutravision is intended for long-term maintenance alongside existing eye care for people who want to do more to support macular health and, being zinc free, may be preferred for those who are sensitive to zinc or already taking zinc containing formulations.

Visit: nutravision.com.au or contact: info@nutravision.com.au

OphthalmoPro provides clinicians with advanced technologies that support the detection and management of macular disease. The new Microclear SKY Whole Eye imaging system delivers comprehensive retinal imaging with high-resolution visualisation of the posterior segment, in the form of widefield fundus photography (135°) combined with widefield optical coherence tomography, assisting clinicians in identifying structural changes associated with macular conditions such as age-related macular degeneration (AMD).

Complementing these diagnostic capabilities, Espansione’s AMD Eye-light device is now officially available in New Zealand, offering photobiomodulation light-based therapy for the management of early to intermediate dry AMD. Together, these technologies support a more integrated approach to macular care, enabling improved screening, monitoring, and non-invasive treatment pathways.

By combining advanced imaging with emerging therapeutic options, OphthalmoPro aims to support earlier detection and improve clinical management of macular disease.

Contact: Ophthalmopro (AUS) 1300 578 288 or (NZ) 0800 578 288 or visit ophthalmopro.com.au

The MonacoPro is Optos’ most advanced ultra-widefield imaging solution, combining optomap 200° ultra-widefield scanning laser ophthalmoscopy (SLO) with Spectral Domain optical coherence tomography (OCT).

MonacoPRO helps eye health specialists detect 29.4% more macular pathologies compared to ultra-widefield imaging alone.1

Engineered for efficiency, it captures up to five imaging modalities for both eyes in just 90 seconds, optimising workflow, streamlining diagnostics, and delivering superior patient care.

Why Choose MonacoPRO?

• Sharp, detailed Spectral Domain OCT imaging. Improves diagnostic accuracy and clinical outcomes,
• New AreaAssist tool. Automates and simplifies retinal imaging, saving valuable time, and
• Reference database. Improves glaucoma detection through optic nerve head analysis.

Visit: optos.com or email auinfo@optos.com

As eye care professionals, you’re often the first to diagnose permanent vision loss, and the one your patient looks to next. Once the clinical plan is explained, many are left wondering, “What does this mean for my driving? My work? My independence?”.

SeeWay is here to support what happens next. SeeWay provides lifestyle and early-intervention support for people with permanent low vision who may not yet qualify for government-funded care. Beyond the clinical appointment, SeeWay offers access to no-gap counselling, personalised digital literacy training, and carefully curated information to help patients adapt with confidence.

SeeWay also guides practical next steps and connects patients to trusted services nationwide. SeeWay complements your care by addressing the emotional and functional impact of vision loss, so your patients feel supported, informed, and empowered between appointments. SeeWay is a free service, available nationwide.

Visit: seeway.com.au or contact (AUS) 1800 733 929

The BMizar 400K optical coherence tomography (OCT) /OCT angiography device delivers next-generation retinal and anterior segment imaging with an ultra-fast 400,000 A-scans per second next generation swept-source engine. Its ultra-widefield scanning capability captures expansive retinal views while maintaining exceptional micro-level detail of retinal layers and vasculature using dye-free OCT angiography.

Multiple scan protocols enable detailed assessment of the macula, optic nerve head, and retinal microvasculature, supporting the diagnosis and monitoring of glaucoma, age-related macular degeneration, diabetic retinopathy, and other retinal disease. Dedicated anterior segment OCT allows visualisation of the cornea, anterior chamber angle, and anterior chamber structures for comprehensive ocular assessment.

Advanced motion correction, automated segmentation, and quantitative analytics ensure reliable, repeatable measurements in busy clinical environments.

Contact: Spectrum Surgical (AUS) 03 9562 2472 or (NZ) 09 888 9100

Australian made and owned Macutec is an ideal product to support patients’ eye health. Manufactured in an Australian pharmaceutical facility using the highest quality raw materials, Macutec is recommended by eye health specialists in many countries around the world.

Macutec Once Daily is available in a 120 capsule economy pack for affordability and patient purchasing convenience, with each pack lasting a full four months. In response to optometrist feedback, Macutec Once Daily 60 packs are available in optometrist exclusive packs without a reorder phone number on the label.

Contact: Stiltec (AUS) 1800 622 883

The rise of anti-VEGF injections has provided new treatment possibilities for countless patients but also delivered a new challenge: more people need injections than ever before.

The SP.Eye device was developed by ophthalmologists to make injections safer, quicker, and more comfortable for patients. The device is easy to use and suitable for ophthalmologists and allied healthcare professionals. No speculum or drape is required, making the procedure more comfortable for patients, significantly reducing the time required to perform injections, and reducing the amount of medical waste associated with intravitreal injections.

SP.Eye is sharps safe as the needle tip is tucked away and inaccessible after use.

Contact: SurgiVision (AUS) 1300 995 132 or (NZ) 02 8999 3323

Intravitreal injections have surged with the rise of macular diseases. TSK Laboratory International is addressing this by introducing SteriJect ophthalmic needles. SteriJect is approved for ophthalmic use and engineered for precise delivery of anti-VEGF medications.

TSK’s innovative Low Dead Space (LDS) technology minimises the space within the syringe-hub assembly, preventing air bubbles and reducing waste from sight-saving biologics. The hub geometry drives faster, cleaner flow, while the hard polymer construction ensures safe, secure attachment during injection. Partnering this advanced hub, TSK’s 33G and 34G profiles, with TSKiD technology, require less force for scleral penetration and intravitreal injection, minimising tissue damage, and discomfort. By prioritising patient safety and comfort, TSK is continually elevating the standard of ophthalmic care.

Contact: TSK Lab (AUS) 02 8077 9815 or visit shopaus.tsklab.com

For 25 years, Macular Disease Foundation Australia (MDFA) has been the national peak body representing the interests of the estimated 1.9 million Australians who live with a macular disease. As the representative voice, MDFA influences Australian health, aged care, and disability agendas, to improve outcomes for patients, their families, and carers.

The Foundation provides evidence-based leadership to reduce the impact of macular disease through four key pillars of work:

Community awareness and early detection. National awareness/engagement campaigns and working in partnership with eye health professionals to promote regular eye screening. Support for living with macular disease. Free evidence-based information and resources, a National Helpline, and other practical service interventions. Advocacy. For initiatives that reduce the impact of macular disease and improve the quality of life and independence of the MDFA community. Research. For a future to prevent and cure macular disease.

Refer your patients with macular disease to MDFA for education and support.

Visit: mdfoundation.com.au

Rather than being a scan protocol, the Advanced Retinal Pigment Epithelium (RPE) Analysis, available on ZEISS Cirrus optical coherence tomography (OCT), is a combination of two algorithms that can be applied to any macular cube scan to measure RPE elevations for mapping drusen and sub-RPE slab illumination. This helps detect areas of geographic atrophy (GA) and their proximity to the fovea, as well as progression or encroachment onto the fovea.

As the Advanced RPE Analysis requires no additional scan captures, it can be retrospectively applied to any macular cube scan captured on your ZEISS Cirrus OCT.
Furthermore, ZEISS Cirrus Pathfinder represents the latest addition to the ZEISS OCT portfolio. Trained on more than 75,000 B-scans, Cirrus Pathfinder is a decision support tool, powered by artificial intelligence, that detects B-scans in any Cirrus macula cube scan that show signs of pathology, including RPE elevations and atrophy.

Contact: ZEISS Account Manager

The Revo HR provides ultra-high-resolution, ultra-widefield optical coherence tomography (OCT) imaging with integrated colour fundus imaging, enabling clinicians to assess retinal structure with one examination.

Operating at 130,000 A-scans per second with axial resolution at the level of 3 μm in tissue (1.4 μm digital), the system provides unique visualisation of retinal layers, taking precision, accuracy, and detection of even the finest lesions to a whole new level.

The Revo HR is an all-in-one device that can be used in a number of ways, such as a full colour fundus camera or as a combo, providing simultaneous OCT and fundus images for high quality OCT imaging, including OCT-A.

Visit: optopol.au